Evidence map›Paper›PMID 40935615›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

How Rapidly Does the FAPI PET Signal Reverse Following Therapy? Assessing the FAPI PET Signal in Hypertensive Cardiac Injury and Fibrosis in Mice.

Atefeh Hosseini, Elias Haj-Yehia, Sebastian Korste, Yalcin Kuzay, Marija Trajkovic-Arsic, Stephan Settelmeier, Miriam Cantore, Katja B Ferenz, Jens T Siveke, Ken Herrmann and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Atefeh HosseiniDepartment of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Elias Haj-YehiaDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sebastian KorsteDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Yalcin KuzayDepartment of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Marija Trajkovic-ArsicBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Stephan SettelmeierDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Miriam CantoreInstitute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and.
Katja B FerenzInstitute of Physiology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; and.
Jens T SivekeBridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ken HerrmannDepartment of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Tienush RassafDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Ulrike Hendgen-CottaDepartment of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wolfgang A WeberDepartment of Nuclear Medicine, Klinikum rechts der Isar der TUM, Munich, Germany.
Zohreh VarastehDepartment of Nuclear Medicine, Medical Faculty, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; zohreh.varasteh@uk-essen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reactive fibrosis is a complex response to chronic myocardial insults, contributing to heart failure progression. Fibroblast activation protein inhibitor (FAPI) PET shows promise in distinguishing active from established fibrosis. Although antifibrotic therapies may improve left ventricular (LV) function in preclinical studies, their clinical application is limited by the lack of noninvasive imaging methods to assess fibrosis regression. This study investigates the potential of FAPI PET to track the therapeutic transition of activated fibroblast activation protein (FAP)-positive fibroblasts toward a FAP-negative phenotype.

Indexed as

GelatinasesHeart InjuriesHypertensionMembrane ProteinsPositron-Emission TomographyPositron Emission Tomography Computed TomographySerine EndopeptidasesAnimalsEndopeptidasesFibroblast Activation Protein AlphaFibrosisGallium RadioisotopesMaleMiceMice, Inbred C57BLMyocardiumEndopeptidasesFibroblast Activation Protein AlphaGallium RadioisotopesGelatinasesMembrane ProteinsSerine EndopeptidasesFAPI PETrapid therapy response monitoringsignal reversibility

Identifiers

PMID40935615
PMCPMC12582177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.